Pioneering Neuropsychiatric Solutions
Innovative Therapies for a Healthier Mind
Discover how Synendos is transforming the landscape of neuropsychiatric treatment through groundbreaking research and development.
Our Mission and Vision
Synendos is dedicated to advancing the treatment of neuropsychiatric disorders by developing innovative therapies that restore natural brain function. Our mission is to provide safe, effective solutions that significantly improve the quality of life for patients worldwide.
Harnessing the Power of the Endocannabinoid System
At Synendos, we focus on the endocannabinoid system (ECS) as a pivotal pathway for developing novel therapies. Our research aims to unlock the ECS’s potential to restore balance within the brain.
Selective Endocannabinoid Re-uptake Inhibitors (SERIs)
Our lead drug candidate, SYT-510, is part of a groundbreaking class of ECS modulators known as SERIs, which offer a self-limiting mechanism of action to enhance patient outcomes.
Innovative Drug Development
We are committed to pioneering new chemical entities that represent first-in-class solutions for neuropsychiatric conditions, setting new standards in therapeutic innovation.
Patient-Centric Approach
Our therapies are designed with the patient in mind, aiming to deliver meaningful benefits and improve overall mental health and well-being.
Collaborative Research
Synendos collaborates with leading scientists and institutions to push the boundaries of neuroscience and bring cutting-edge treatments to market.
What Experts Are Saying
„Synendos is at the forefront of neuropsychiatric treatment innovation, offering hope to countless patients.“
Dr. Emily Carter, Neuroscience Researcher
„The groundbreaking work on the endocannabinoid system by Synendos could redefine therapeutic approaches.“
Prof. Michael Thompson, Pharmacology Expert
„SYT-510 represents a promising advancement in mental health care, with its unique mechanism of action.“
Dr. Sarah Lee, Clinical Psychologist
Meet Our Experts
Our team is composed of leading professionals dedicated to pioneering advancements in neuroscience and drug development.
Dr. John Smith
Chief Scientific Officer
Dr. Anna Brown
Head of Drug Development
Dr. Mark Wilson
Neuroscience Research Lead
Join Us on Our Mission
Explore the transformative potential of Synendos‘ therapies. Learn how we are shaping the future of neuropsychiatric treatment.